Mizuho lowered the firm’s price target on Nkarta (NKTX) to $16 from $20 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. The firm removed the potential contribution of NKX019 in large B-cell malignancies, upon Nkarta announcing that it will no longer further development in this indication.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX: